The Cystic Fibrosis Foundation has agreed to provide Prime Medicine Inc. an additional investment of up to $24 million to ...

Boehringer Ingelheim Stiftung announces the winner of the 2025 Heinrich Wieland Prize: Adrian R. Krainer of Cold Spring ...

Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

The two companies will scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

I think the best description of attitudes toward gene editing is ambivalence. About 30% of the public thinks this is a good idea, and the exact same share thinks it’s a bad idea. The plurality ...

Children and adults with rare forms of cystic fibrosis in England will be able to access triple-combination therapy. Vanzacaftor–tezacaftor–deutivacaftor (Alyftrek®), is the latest in a new generation ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently available drug Kaftrio.

Autonomy, confidence and competence were stronger predictors of wellbeing than more traditional measures like deprivation or ...

A Ph.D. graduate student in biomolecular engineering at UC Santa Cruz, with a background in computer science and mathematics, ...

Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets. Enbridge has a lower risk ...

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.